Research Directory Details | National Medical Research Register

A Phase I study on the Safety Allogeneic Human Umbilical Cord Mesenchymal Stem Cells(PF2020-CELL) for Perianal Fistulas in patients with Crohn`s disease

A Phase I study on the Safety Allogeneic Human Umbilical Cord Mesenchymal Stem Cells(PF2020-CELL) for Perianal Fistulas in patients with Crohn`s disease

Stem Cell Therapy for Perianal Fistulas in Crohn's Disease

General Information
Research Type
Interventional
Description
Primary: To demonstrate the safety of allogeneic UC-MSCs administered by injection for complex perianal fistulas in patients with Crohn`s disease
Secondary: To determine the efficacy of a single/multiple allogeneic UC-MSCs injection in improving complex perianal fistula complications and (re-epithelialization of the external openings).

In this study, a total of 5 patients will be recruited which includes a consideration of 20% (one patient) dropout from the trial.

Duration of Study: 1 year (52 weeks)
Study Information
RMK Priority Area
Non-Communicable Disease
Research Level
Clinical Practice
Research Keyword
Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs); perianal fistula; Crohn's disease
Inclusion & Exclusion Criteria
Inclusion Criteria
Adult men and women age 18 years and above|Diagnosis of perianal fistulae associated with Crohn's disease refractory to medical therapy|Presence of perianal fistula(s) with a maximum of 2 internal openings and a maximum of 3 external openings based on clinical assessment.|Fit for surgery
Exclusion Criteria
Informed consent refusal|Pregnancy or breastfeeding women|Current diagnosis of active cancer or remission for less than 5 years|Evidence of active sepsis or significant localised infection|Patients with HIV, HBV, HCV or treponema infection, whether active or latent|Patients with documented allergies.|Patients who have received infliximab or any other biologics in the 4 weeks before the cell treatment administration|Patients currently receiving, or having received within 1 month prior to enrolment into this clinical trial, any investigational drug|Patients with any other co-morbidity/ co-pathologies which is deemed as contraindication to stem cells infusion (infection, administration of steroids)
Study Timeline
Expected / Actual Date Study Starts - First Enrolment of subject / Collecting data
Aug, 01 2022
Expected / Actual Date Study Completed
Jan, 27 2025
Expected / Actual Duration of Study Enrollment / Data Collection
130 weeks